4//SEC Filing
Brumm Joshua T 4
Accession 0000950170-24-030479
CIK 0001818794other
Filed
Mar 11, 8:00 PM ET
Accepted
Mar 12, 9:56 PM ET
Size
26.1 KB
Accession
0000950170-24-030479
Insider Transaction Report
Form 4
Brumm Joshua T
DirectorSee Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-03-08$5.54/sh+153,931$852,778→ 708,316 total - Sale
Common Stock
2024-03-08$26.72/sh−160,670$4,293,102→ 554,820 total - Exercise/Conversion
Common Stock
2024-03-08$5.54/sh+209,412$1,160,142→ 917,728 total - Sale
Common Stock
2024-03-08$25.30/sh−202,238$5,116,621→ 715,490 total - Exercise/Conversion
Stock option (right to buy)
2024-03-08−209,412→ 133,269 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (209,412 underlying) - Sale
Common Stock
2024-03-08$27.38/sh−435$11,910→ 554,385 total - Sale
Common Stock
2024-03-11$25.93/sh−8,618$223,465→ 537,998 total - Exercise/Conversion
Common Stock
2024-03-11$5.54/sh+50,000$277,000→ 604,385 total - Sale
Common Stock
2024-03-11$25.42/sh−40,072$1,018,630→ 564,313 total - Sale
Common Stock
2024-03-11$26.10/sh−9,928$259,121→ 554,385 total - Sale
Common Stock
2024-03-11$26.12/sh−7,769$202,926→ 546,616 total - Exercise/Conversion
Stock option (right to buy)
2024-03-08−153,931→ 0 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (153,931 underlying) - Exercise/Conversion
Stock option (right to buy)
2024-03-11−50,000→ 83,269 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (50,000 underlying)
Footnotes (11)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.20 to $26.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F10]The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.
- [F11]The option was granted on July 31, 2020. The shares underlying the option vest over four years in sixteen equal installments beginning on October 31, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.20 to $27.18, inclusive.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.27 to $27.49, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.75, inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.01 to $26.10, inclusive.
- [F6]Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.22 to $26.18, inclusive.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.68 to $26.05, inclusive.
- [F9]Includes 513,913 unvested RSUs.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001528826
Filing Metadata
- Form type
- 4
- Filed
- Mar 11, 8:00 PM ET
- Accepted
- Mar 12, 9:56 PM ET
- Size
- 26.1 KB